Ivaltinostat is under clinical development by CG Invites and currently in Phase I for Alport Syndrome. According to GlobalData, Phase I drugs for Alport Syndrome have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ivaltinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ivaltinostat overview
Ivaltinostat is under development for the treatment of metastatic pancreatic ductal adenocarcinoma, myelodysplastic syndrome, acute myeloid leukemia, hepatocellular carcinoma, idiopathic pulmonary fibrosis (IPF), alport syndrome, nonalcoholic steatohepatitis, chronic kidney disease and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intravenous and oral route. It is a small molecule acts by targeting HDAC enzyme. It is developed based on SPS technology, SCP technology and SDF technology.
CG Invites overview
CG Invites, formerly CrystalGenomics is a biopharmaceutical company that discovers and develops structural chemoproteiomics-based drugs. The company’s pipeline products include CG-650 for osteoarthritis CG-651, targeting neuropathic pain; CG-598 against inflammatory bowel disease; CG-549 used for the treatment of infectious diseases; CG-745 investigating for the treatment of pancreatic cancer, myelodysplastic syndrome and acute myeloid leukemia; CG-806, against blood cancer and CG-750 for treating fibrosis. CG Invites uses its proprietary technologies to determine the structure of proteins, generate lead compounds; and optimize novel leads to drug candidate compounds. The company also provides soluble, active and homogeneous forms of disease-related proteins. CG Invites is headquartered in Seongnam, South Korea.
For a complete picture of Ivaltinostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
